Benzinga.com

Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks

Altimmune Inc. (NASDAQ: ALT) on Friday shared topline results from the IMPACT Phase 2b trial of pemvidutide. Patients had metabolic dysfunction-associated steatohepatitis (MASH) at 48 weeks. MASH is a ...
Benzinga.com

What's Going On With Altimmune (ALT) Stock Today?

Altimmune Inc (NASDAQ:ALT) shares jumped 8.5% to $5.61 on Friday, ahead of next week’s presentation at the European Association for the Study of the Liver International Liver Congress 2025. The stock ...
Seeking Alpha

Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in ...

GAITHERSBURG, Md., June 05, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT) (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented new data on the potential anti-inflammatory and ...

My LFT is slightly high, but I feel fine”: Doctors explain when borderline liver reports turn dangerous and what should be the immediate preventive measures

LFT slightly high. There is no pain. No yellowing of the eyes. No weakness. So it is easy to brush it aside. But the liver rarely shouts in the beginning. It whispers.Liver Function Tests, or LFTs, ...